[{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pharmacosmos AS \/ Pharmacosmos AS","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pharmacosmos AS \/ Pharmacosmos AS","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Pharmacosmos AS","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacosmos AS \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacosmos AS \/ Icon Plc"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Trilaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0.40999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Pharmacosmos AS","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Pharmacosmos AS","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Pharmacosmos AS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Through the acquisition, Pharmacosmos will leverage G1' intellectual property and the addition of Cosela (trilaciclib), which is indicated for treating metastatic triple-negative breast cancer.

                          Product Name : Cosela

                          Product Type : Other Small Molecule

                          Upfront Cash : $405.0 million

                          July 08, 2024

                          Lead Product(s) : Trilaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : G1 Therapeutics, Inc

                          Deal Size : $405.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          February 06, 2023

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Recipient : Peking Union Medical College Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 23, 2023

                          Lead Product(s) : SP-420

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Icon Plc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.

                          Product Name : MonoFerric

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          September 09, 2022

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Zydus Lifesciences

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Alberta Health services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Monoferric

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          February 28, 2022

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Recipient : Brigham and Women's Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          January 05, 2022

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 04, 2021

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Recipient : P. Noordzij

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Monofer® is the first of the latest generation of innovative IV irons to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.

                          Product Name : Monofer

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          January 29, 2021

                          Lead Product(s) : Ferric Derisomaltose

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank